SomaLogic merger overcomes investor objections to win shareholder approval
BOULDER — SomaLogic Inc. (Nasdaq: SLGC) said Thursday evening that its $1 billion merger with California-based Standard BioTools Inc. (Nasdaq: LAB) is expected to be finalized Friday after shareholders for the Boulder biotech company voted this week to consummate the combination.
The apparent approval came despite opposition from investors, including from private-equity firms that hold significant positions in the company as well as from SomaLogic’s founder and its chief technology officer.
“We are grateful for the support of our stockholders as we advance our value-maximizing transaction with Standard BioTools, which will enable our stockholders…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.
-
Gogo Inc. (Nasdaq: GOGO), a Broomfield-based provider of broadband connectivity services for the business aviation…
-
Arca Biopharma's board of directors late last week approved a 1-for-12 reverse stock split in…
-
A Larimer County District Court judge has appointed a receiver for North Shore Manor nursing…
